However, these mutations seem to require additional genetic lesions to drive T-ALL, including gain-of-function alterations in transcriptional factors such as LYL1, HOXA, TAL1, TLX1, and TLX3 (Van Vlierberghe and Ferrando, 2012). The gene discussed is LYL1; the disease is acute lymphoblastic leukemia.